Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
TheFly reported on June 15 that Citizens reiterated its positive stance on MIRM, increasing its price objective to $146 from $140.
Mirum Pharmaceuticals Inc. (MIRM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 70,000,000 | $209,440,280 | 2.47% | ||
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,584,727 | $146,397,080 | +6% | 4.66% |
| 3. | Tang Capital Management Kevin C. Tang | 1,236,027 | $114,184,174 | 5.8% | |
| 4. | Citadel Investment Group Ken Griffin | 1,052,048 | $97,188,194 | +26% | 0.02% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 811,294 | $74,947,340 | +7% | 4.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.48 | 131,425 | $8,999,984.00 | 459,010 | 2026-01-23 | Filing | |
| $43.93 | 21 | $922.61 | 168,672 | 2025-03-17 | Filing | |
| $44.11 | 528 | $23,291.40 | 168,651 | 2025-03-14 | Filing | |
| $43.77 | 963 | $42,155.13 | 168,123 | 2025-03-11 | Filing | |
| $43.37 | 577 | $25,023.34 | 167,160 | 2025-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $101.95 | 2,594 | $264,458.30 | 5,835 | 2026-06-17 | Filing | |
| $95.12 | 1,567 | $149,053.04 | 44,788 | 2026-06-08 | Filing | |
| $93.95 | 1,175 | $110,391.25 | 46,355 | 2026-06-08 | Filing | |
| $92.84 | 2,258 | $209,632.72 | 47,530 | 2026-06-08 | Filing | |
| $99.66 | 883 | $87,999.78 | 194,309 | 2026-06-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,679,684 | $709,449,208 | 18.25% | |
| 2. | 6,945,813 | $641,764,403 | 0.31% | |
| 3. | 3,846,530 | $355,342,442 | 0.01% | |
| 4. | 2,414,776 | $223,077,007 | 0% | |
| 5. | 1,965,375 | $181,561,365 | 0.01% |
News See All
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
12 Best High Short Interest Stocks With Highest Upside Potential
On May 29, Melissa Brown, Managing Director of Investment Decision Research, joined BNN Bloomberg to assess the health of the US economy.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Mirum Pharmaceuticals, Inc. First Quarter 2026 earnings conference call. My name is Tracy, and I will be your operator today.
15 Most Promising Stocks Under $100 to Buy
On March 12, Roger Ferguson, former Fed Vice Chair, joined 'Closing Bell' on CNBC to discuss what to expect from the Federal Reserve next week.
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?
On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Should You Invest in Mirum Pharmaceuticals (MIRM)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter.